Geneva, Switzerland and Boston, MA - November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Company Management will host an R&D Investor Day on Friday December 7th at 8:30 a.m. Eastern Time at the Marriott East Side in New York City.
- Meeting registration and breakfast will start at 8:30 a.m. ET, and presentations will take place from 9:00 a.m.-12:00 p.m. ET.
- To register to attend this event, please email Carolyn Curran of LHA Investor Relations at Ccurran@lhai.com (mailto:Ccurran@lhai.com)
A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.
For further information, please contact:
Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile
Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4017 Office
+1 646 537 5649 Mobile
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Attachment
- Press Release in Pdf (https://prlibrary-eu.nasdaq.com/Resource/Download/ac5a87e1-b963-4149-bd13-4727ce7a7723)
